Aarti Pharmalabs Limited (IN:AARTIPHARM)
:AARTIPHARM
Want to see IN:AARTIPHARM full AI Analyst Report?
AARTIPHARM Stock Chart & Stats
₹842.40
₹9.55(1.45%)
At close: 4:00 PM EST
₹842.40
₹9.55(1.45%)
Day’s Range― - ―
52-Week Range₹583.85 - ₹971.50
Previous CloseN/A
Volume141.60K
Average Volume (3M)18.67K
Market Cap
₹56.44B
Enterprise Value₹64.86B
Total Cash (Recent Filing)₹555.56M
Total Debt (Recent Filing)₹6.59B
Price to Earnings (P/E)31.3
Beta0.86
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.67%
Share Statistics
EPS (TTM)26.45
Shares Outstanding90,657,750
10 Day Avg. Volume12,195
30 Day Avg. Volume18,670
Financial Highlights & Ratios
PEG Ratio-0.92
Price to Book (P/B)2.71
Price to Sales (P/S)3.16
P/FCF Ratio-30.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B API & Intermediates ManufacturingThe company's core B2B model supplying APIs and intermediates to formulators is structurally durable: long product development cycles, technical process expertise and industrial-scale manufacturing create sticky customer relationships and steady volume-driven revenue potential over the medium term.
Historically Solid MarginsSustained operating and net margins across multiple years indicate effective process chemistry, cost control, and product mix advantages. These entrenched margin dynamics provide a buffer against cyclical revenue swings and support reinvestment or deleveraging when top-line recovers.
Positive Operating Cash FlowConsistently positive operating cash flow suggests core operations generate cash even amid volatility. This underlying cash generation supports working capital, funds incremental capex, and reduces dependency on external financing if management prioritizes cash conversion improvements.
Bears Say
Recent Revenue & Earnings DeclineA concrete decline in FY2026 revenue and sharply lower net income point to demand softness, pricing pressure, or product mix shifts. Persistent top-line weakness would erode margins, limit free cash flow recovery, and constrain the company's ability to invest or reduce leverage over the coming months.
Material Increase In LeverageA meaningful rise in borrowings increases interest burden and reduces financial flexibility. Higher leverage heightens refinancing and covenant risk if earnings remain depressed, limiting strategic options and making the company more sensitive to interest-rate and working-capital shocks.
Negative Free Cash Flow TrendSustained negative free cash flow indicates capex or working-capital needs are absorbing operating cash, forcing reliance on debt or external funding. Until FCF turns positive, the company faces constrained investment capacity and elevated funding risk, impacting long-term resilience.
Aarti Pharmalabs Limited News
AARTIPHARM FAQ
What was Aarti Pharmalabs Limited’s price range in the past 12 months?
Aarti Pharmalabs Limited lowest stock price was ₹583.85 and its highest was ₹971.50 in the past 12 months.
What is Aarti Pharmalabs Limited’s market cap?
Aarti Pharmalabs Limited’s market cap is ₹56.44B.
When is Aarti Pharmalabs Limited’s upcoming earnings report date?
Aarti Pharmalabs Limited’s upcoming earnings report date is Aug 03, 2026 which is in 58 days.
How were Aarti Pharmalabs Limited’s earnings last quarter?
Aarti Pharmalabs Limited released its earnings results on May 25, 2026. The company reported ₹6.74 earnings per share for the quarter, beating the consensus estimate of N/A by ₹6.74.
Is Aarti Pharmalabs Limited overvalued?
According to Wall Street analysts Aarti Pharmalabs Limited’s price is currently Overvalued.
Does Aarti Pharmalabs Limited pay dividends?
Aarti Pharmalabs Limited pays a Semiannually dividend of ₹2.5 which represents an annual dividend yield of 0.67%. See more information on Aarti Pharmalabs Limited dividends here
What is Aarti Pharmalabs Limited’s EPS estimate?
Aarti Pharmalabs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aarti Pharmalabs Limited have?
Aarti Pharmalabs Limited has 90,657,750 shares outstanding.
What happened to Aarti Pharmalabs Limited’s price movement after its last earnings report?
Aarti Pharmalabs Limited reported an EPS of ₹6.74 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.666%.
Which hedge fund is a major shareholder of Aarti Pharmalabs Limited?
Currently, no hedge funds are holding shares in IN:AARTIPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, new chemical entities, and xanthine derivatives in India. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India.
Technical Analysis
Aarti Drugs Limited
―
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Glenmark Pharmaceuticals Limited
―
Laurus Labs Ltd.
―